Previous 10 | Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - February 1, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
110,000 square-foot state-of-the-art facility supports significantly expanded product manufacturing capacity and will enable new product introductions Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality syntheti...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the openin...
Summary Let's continue our roundtable series with Growth, Tech and Crypto, and Quantitative, Technical analysis coverage. Nine of our Marketplace contributors give their analysis and share one top idea. We end the series with Biotech and Healthcare coverage. ~ By Ashutosh Go...
Combining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary cancer around the world Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offerin...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a research collaboration with Astellas Pharma Inc . (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...
Summary Twist operates in a trendy space, with good growth, but atrocious margins. As profits are not in the company’s DNA, losses are likely to continue. Although the stock is down a lot, it still trades at a healthy valuation. The stock has limited downside protection i...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 41st Annual J.P. Morgan He...
New York, New York--(Newsfile Corp. - December 20, 2022) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit. The lawsuit on behalf of Twist investors has been commenced in the the United ...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...